A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers

BACKGROUND: The combination of paclitaxel and cetuximab (PaCe) has led to an encouraging response rate in Phase 2 setting with limited toxicity. The aim of our study was to assess the efficacy of this regimen in our setting in platinum sensitive and nonsensitive patients. METHODS: This was a retrosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Noronha, Vanita, Patil, Vijay M., Joshi, Amit, Bhattacharjee, Atanu, Paul, Davinder, Dhumal, Sachin, Juvekar, Shashikant, Arya, Supreeta, Prabhash, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
ORIGINAL ARTICLE: Head and Neck Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379885/
https://www.ncbi.nlm.nih.gov/pubmed/28413788
http://dx.doi.org/10.4103/2278-330X.202558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379885/
https://www.ncbi.nlm.nih.gov/pubmed/28413788
http://dx.doi.org/10.4103/2278-330X.202558

Ejemplares similares